BCAX Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -- compared to Bicara Therapeutics, Inc.'s net margin of --. Bicara Therapeutics, Inc.'s return on equity of -26.44% beat CEL-SCI Corp.'s return on equity of -266.61%.

Bicara Therapeutics, Inc. has a consensus price target of $32.57, signalling upside risk potential of 78.96%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that CEL-SCI Corp. has higher upside potential than Bicara Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Bicara Therapeutics, Inc..

Bicara Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Bicara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicara Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Bicara Therapeutics, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Bicara Therapeutics, Inc.'s net income of -$36.3M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Bicara Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicara Therapeutics, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Dogwood Therapeutics, Inc. has a net margin of -- compared to Bicara Therapeutics, Inc.'s net margin of --. Bicara Therapeutics, Inc.'s return on equity of -26.44% beat Dogwood Therapeutics, Inc.'s return on equity of -121.03%.

Bicara Therapeutics, Inc. has a consensus price target of $32.57, signalling upside risk potential of 78.96%. On the other hand Dogwood Therapeutics, Inc. has an analysts' consensus of $18.33 which suggests that it could grow by 205.05%. Given that Dogwood Therapeutics, Inc. has higher upside potential than Bicara Therapeutics, Inc., analysts believe Dogwood Therapeutics, Inc. is more attractive than Bicara Therapeutics, Inc..

Bicara Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dogwood Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Bicara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dogwood Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicara Therapeutics, Inc. pays -- of its earnings as a dividend. Dogwood Therapeutics, Inc. pays out -- of its earnings as a dividend.

Bicara Therapeutics, Inc. quarterly revenues are --, which are smaller than Dogwood Therapeutics, Inc. quarterly revenues of --. Bicara Therapeutics, Inc.'s net income of -$36.3M is lower than Dogwood Therapeutics, Inc.'s net income of -$15.7M. Notably, Bicara Therapeutics, Inc.'s price-to-earnings ratio is -- while Dogwood Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicara Therapeutics, Inc. is -- versus -- for Dogwood Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oncotelic Therapeutics, Inc. has a net margin of -- compared to Bicara Therapeutics, Inc.'s net margin of --. Bicara Therapeutics, Inc.'s return on equity of -26.44% beat Oncotelic Therapeutics, Inc.'s return on equity of -25.13%.

Bicara Therapeutics, Inc. has a consensus price target of $32.57, signalling upside risk potential of 78.96%. On the other hand Oncotelic Therapeutics, Inc. has an analysts' consensus of -- which suggests that it could grow by 4164.39%. Given that Oncotelic Therapeutics, Inc. has higher upside potential than Bicara Therapeutics, Inc., analysts believe Oncotelic Therapeutics, Inc. is more attractive than Bicara Therapeutics, Inc..

Bicara Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oncotelic Therapeutics, Inc. has a beta of -0.758, suggesting its less volatile than the S&P 500 by 175.831%.

Bicara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncotelic Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicara Therapeutics, Inc. pays -- of its earnings as a dividend. Oncotelic Therapeutics, Inc. pays out -- of its earnings as a dividend.

Bicara Therapeutics, Inc. quarterly revenues are --, which are smaller than Oncotelic Therapeutics, Inc. quarterly revenues of --. Bicara Therapeutics, Inc.'s net income of -$36.3M is lower than Oncotelic Therapeutics, Inc.'s net income of -$1.1M. Notably, Bicara Therapeutics, Inc.'s price-to-earnings ratio is -- while Oncotelic Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicara Therapeutics, Inc. is -- versus -- for Oncotelic Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Bicara Therapeutics, Inc.'s net margin of 21.32%. Bicara Therapeutics, Inc.'s return on equity of -26.44% beat Pfizer Inc.'s return on equity of 10.84%.

Bicara Therapeutics, Inc. has a consensus price target of $32.57, signalling upside risk potential of 78.96%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 11.56%. Given that Bicara Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Bicara Therapeutics, Inc. is more attractive than Pfizer Inc..

Bicara Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Bicara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.61% to investors and pays a quarterly dividend of $0.43 per share. Bicara Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Bicara Therapeutics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Bicara Therapeutics, Inc.'s net income of -$36.3M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Bicara Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 15.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicara Therapeutics, Inc. is -- versus 2.37x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.